For at least the last five years, drug companies have been complaining that venture capitalists, focused on in-licensing, have abandoned investments in novel technologies. An exaggeration, to be sure--given the large number, for example, of new large-molecule start-ups. But certainly directionally correct.
So if the VCs won’t do what you want, do it for them. Or at least with them. On July...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?